There is an application for approval of the Johnson & Johnson vaccine in the EU

The vaccine will be assessed by the EMA Human Medicines Committee (CHMP). The opinion may be issued by mid-March 2021, provided that the research results provided by the company regarding the effectiveness, safety and quality of the vaccine are sufficiently comprehensive and reliable.

If EMA concludes that the benefits of the vaccine outweigh its risks, it will recommend conditional marketing authorization. Then, the European Commission will decide on the marketing authorization in all EU and EEA (European Economic Area) Member States.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.